Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Amer M. Zeidan; Pierre Fenaux; Marco Gobbi; Jiří Mayer; Gail J. Roboz; Jürgen Krauter; Tadeusz Robak; Hagop M. Kantarjian; Jan Novák; Wieslaw W. Jedrzejczak; Xavier Thomas; Mario Ojeda-Uribe; Yasushi Miyazaki; Yoo Hong Min; Su Peng Yeh; Joseph M. Brandwein; Liana Gercheva; Judit Demeter; Elizabeth A. Griffiths; Karen W.L. Yee; Jean Pierre J. Issa; Jan Philipp Bewersdorf; Harold Keer; Yong Hao; Mohammad Azab; Hartmut Döhner

doi:10.1182/blood.2022015832

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Amer M. Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J. Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novák, Wieslaw W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su Peng Yeh, Joseph M. Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen W.L. YeeJean Pierre J. Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner

Leukemia

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	285-289
Number of pages	5
Journal	Blood
Volume	140
Issue number	3
DOIs	https://doi.org/10.1182/blood.2022015832
State	Published - Jul 21 2022

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2022015832

Cite this

Zeidan, A. M., Fenaux, P., Gobbi, M., Mayer, J., Roboz, G. J., Krauter, J., Robak, T., Kantarjian, H. M., Novák, J., Jedrzejczak, W. W., Thomas, X., Ojeda-Uribe, M., Miyazaki, Y., Min, Y. H., Yeh, S. P., Brandwein, J. M., Gercheva, L., Demeter, J., Griffiths, E. A., ... Döhner, H. (2022). Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood, 140(3), 285-289. https://doi.org/10.1182/blood.2022015832

Zeidan, AM, Fenaux, P, Gobbi, M, Mayer, J, Roboz, GJ, Krauter, J, Robak, T, Kantarjian, HM, Novák, J, Jedrzejczak, WW, Thomas, X, Ojeda-Uribe, M, Miyazaki, Y, Min, YH, Yeh, SP, Brandwein, JM, Gercheva, L, Demeter, J, Griffiths, EA, Yee, KWL, Issa, JPJ, Bewersdorf, JP, Keer, H, Hao, Y, Azab, M & Döhner, H 2022, 'Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy', Blood, vol. 140, no. 3, pp. 285-289. https://doi.org/10.1182/blood.2022015832

@article{5f8564c23bec42fabdf893a313610a79,

title = "Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy",

author = "Zeidan, {Amer M.} and Pierre Fenaux and Marco Gobbi and Ji{\v r}{\'i} Mayer and Roboz, {Gail J.} and J{\"u}rgen Krauter and Tadeusz Robak and Kantarjian, {Hagop M.} and Jan Nov{\'a}k and Jedrzejczak, {Wieslaw W.} and Xavier Thomas and Mario Ojeda-Uribe and Yasushi Miyazaki and Min, {Yoo Hong} and Yeh, {Su Peng} and Brandwein, {Joseph M.} and Liana Gercheva and Judit Demeter and Griffiths, {Elizabeth A.} and Yee, {Karen W.L.} and Issa, {Jean Pierre J.} and Bewersdorf, {Jan Philipp} and Harold Keer and Yong Hao and Mohammad Azab and Hartmut D{\"o}hner",

note = "Funding Information: A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research and was also supported by a National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award. Research reported in this publication was supported in part by the NCI, National Institutes of Health (award P30 CA016359). This study was supported by research funding from ASTEX Pharmaceuticals, Inc. ",

year = "2022",

month = jul,

day = "21",

doi = "10.1182/blood.2022015832",

language = "English (US)",

volume = "140",

pages = "285--289",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "3",

}

TY - JOUR

T1 - Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

AU - Zeidan, Amer M.

AU - Fenaux, Pierre

AU - Gobbi, Marco

AU - Mayer, Jiří

AU - Roboz, Gail J.

AU - Krauter, Jürgen

AU - Robak, Tadeusz

AU - Kantarjian, Hagop M.

AU - Novák, Jan

AU - Jedrzejczak, Wieslaw W.

AU - Thomas, Xavier

AU - Ojeda-Uribe, Mario

AU - Miyazaki, Yasushi

AU - Min, Yoo Hong

AU - Yeh, Su Peng

AU - Brandwein, Joseph M.

AU - Gercheva, Liana

AU - Demeter, Judit

AU - Griffiths, Elizabeth A.

AU - Yee, Karen W.L.

AU - Issa, Jean Pierre J.

AU - Bewersdorf, Jan Philipp

AU - Keer, Harold

AU - Hao, Yong

AU - Azab, Mohammad

AU - Döhner, Hartmut

N1 - Funding Information: A.M.Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research and was also supported by a National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award. Research reported in this publication was supported in part by the NCI, National Institutes of Health (award P30 CA016359). This study was supported by research funding from ASTEX Pharmaceuticals, Inc.

PY - 2022/7/21

Y1 - 2022/7/21

UR - http://www.scopus.com/inward/record.url?scp=85134777585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134777585&partnerID=8YFLogxK

U2 - 10.1182/blood.2022015832

DO - 10.1182/blood.2022015832

M3 - Letter

C2 - 35507690

AN - SCOPUS:85134777585

SN - 0006-4971

VL - 140

SP - 285

EP - 289

JO - Blood

JF - Blood

IS - 3

ER -

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this